Clinical studyBiochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial**
References (24)
- et al.
Effects of two oral doses of alendronate in the treatment of Paget's disease of bone
Bone
(1994) - et al.
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone
Bone Miner
(1994) - et al.
Treatment of Paget's disease with (3-amino-1-hydoxypropylidene)-1,1-bisphosphonate (APD)
Lancet
(1979) - et al.
Reconstruction of the resorption site in iliac trabecular bone: a kinetic model for bone resorption in 20 normal individuals
Met Bone Dis Rel Res
(1984) - et al.
Treatment of Paget's disease of bone
Clin Endocrinol
(1990) - et al.
Clinical and biochemical effects of diphosphonate in Paget's disease of bone
Arthritis Rheum
(1975) - et al.
Diphosphonate therapy of Paget's disease of bone
J Clin Endocrinol Metab
(1977) - et al.
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD)
BMJ
(1987) - et al.
Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate
J Bone Miner Res
(1990)
Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate
Calcif Tissue int
Assessment of pain in cancer
Adv Pain Res Ther
Cited by (163)
Total elbow arthroplasty for elbow osteoarthritis associated with Paget's disease: A case report and review of literature
2024, JSES Reviews, Reports, and TechniquesEndocrinology of Bone and Growth Disorders
2022, Comprehensive PharmacologyRepurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment
2021, Seminars in Cancer BiologyCitation Excerpt :For instance, increasing doses of alendronate reduced urinary excretion of hydroxyproline, a biochemical marker of collagen degradation, in patients with Paget’s disease [23]. Other pharmacodynamic biochemical biomarkers of bone turnover (serum alkaline phosphatase and urine N-telopeptide) also declined and radiological assessment of lytic bone lesions improved after alendronate treatment [32]. The bone anti-resorptive effects of bisphosphonates in osteoporosis suggest that they may also be efficacious in treating osteolysis associated with multiple myeloma and cancers that metastasize to the bone and related complications such as hypercalcemia.
Bisphosphonates—much more than only drugs for bone diseases
2020, European Journal of PharmacologyCitation Excerpt :It was also well tolerated and remained in the bones for a long time (Harinck et al., 1987). The comparative trials with the use of placebo and etidronate as a reference drug showed that alendronate was highly effective in the normalization of the level of ALP in 60–70% of patients (Reid et al., 1996; Siris et al., 1996). Another important observation of the trials with alendronate treatment was a persistent biochemical response to this drug.
Paget's disease of bone
2018, Orthopaedics and Trauma
- **
This study was supported by grants from Merck Research Laboratories.